Volume 25, Number 10—October 2019
Dispatch
Control and Elimination of Extensively Drug-Resistant Acinetobacter baumanii in an Intensive Care Unit
Amanda Chamieh1, Tania Dagher Nawfal1, Tala Ballouz1, Claude Afif, George Juvelekian, Sani Hlais, Jean-Marc Rolain, and Eid Azar
Table 2
Specimen type, site of collection, and microbiologic characteristics in study of carbapenem-sparing regimen for extensively drug-resistant Acinetobacter baumannii in an ICU, Beirut, Lebanon*
| Sequence type, no. (%)¶ | ||
|---|---|---|
| ST2 | 29 (93.5) | 0 |
| ST699 | 1 (3.25) | 0 |
| ST627 | 1 (3.25) | 0 |
| ST25 | 0 | 10 (58.9) |
| ST99 | 0 | 1 (5.8) |
| New STs, 1200–1206 | 0 | 6 (35.3) |
*Bold indicates statistical significance. ESBL, extended-spectrum beta-lactamase; ICU, intensive care unit; MLST, multilocus sequence typing; PCR, polymerase chain reaction; ST, sequence type.
†During February 1, 2016–June 30, 2016, ICU patients received colistin/carbapenem therapy for A. baumannii infections.
‡During July 1, 2016–January 31, 2017, ICU implemented carbapenem-sparing regimen for A. baumannii infections.
§Determined by PCR.
¶Determined by multilocus sequence typing.
1These authors contributed equally to this article.
Page created: September 17, 2019
Page updated: September 17, 2019
Page reviewed: September 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
Content Credential